Regeneron Pharmaceuticals (NASDAQ: REGN) has been a reliable, steadily growing stock over the years, with the top line and profits increasing. The company is coming off a fantastic 2021 as its COVID-19 treatment helped sales reach a record $16 billion -- nearly double the prior year's tally. Below, I'll look at just how well the stock has performed over the past five years and whether Regeneron is a good buy moving forward.

In early August 2017, shares of Regeneron were trading at around $470 per share. Investing $10,000 into the stock back then would have allowed you to buy approximately 21.28 shares in the business. Today, those shares would be worth over $12,400 as the stock has risen a relatively modest 24% during that time. That averages out to a compound annual growth rate of 4.4%.

Those are decent, modest gains but hardly what growth investors would be seeking. Over that five-year stretch, the S&P 500 has far outperformed Regeneron, rising 66% in value.

Continue reading

Source Fool.com